Key result
Pravastatin therapy initiated at the time of complete coronary revascularization was associated with a reduced risk of cardiac mortality in patients with diabetes mellitus.
Why the study?
Does statin therapy initiated at the time of complete revascularization reduce total and cardiac mortality in diabetic patients?
Cohort (n=499)
No
Does statin therapy initiated at the time of complete revascularization reduce total and cardiac mortality in diabetic patients?
Statin therapy initiated at the time of complete coronary revascularization in diabetic patients is associated with a significant reduction in long-term cardiac mortality.
Answers are grounded in this paper and cite their sources.
Supports early statin consideration at revascularization in diabetes; hypothesis-generating and requires RCT confirmation before practice change.
AIM: The long-term effect of statin therapy in diabetic patients after coronary revascularization is not well established. Accordingly, we sought to determine if whether statin therapy initiated at the time of complete revascularization including percutaneous coronary intervention (PCI) and/or bypass surgery reduces total and cardiac mortality among diabetic patients. METHODS: We collected data from 1,138 consecutive patients who underwent complete revascularization (PCI and/or bypass surgery). We then compared all-cause and cardiac mortality rates in 499 patients with diabetes mellitus of whom 149 (29.9%) were treated with statin at the time of revascularization. To adjust the variables that would have been related to the decision regarding statin administration, a propensity score was computed and multivariate Cox regression was carried out. RESULTS: During follow-up (8.8+/-2.6 years), 103 patients died (including 43 who died of cardiac causes). The Multivariate analysis showed statin therapy to be significantly associated with reduced cardiac mortality (HR 0.39, 0.16-0.95; p=0.039), but not with all-cause mortality. CONCLUSION: Statin therapy was associated with a significantly reduced risk of cardiac mortality in patients with diabetes mellitus and coronary artery disease after complete revascularization.
No takes yet. Share an insight, caveat, or question.
Aihara et al. (2010) conducted a cohort in Diabetes mellitus and coronary artery disease (n=499). Pravastatin vs. No statin therapy was evaluated on Cardiac mortality (HR 0.39, 95% CI 0.16-0.95, p=0.039). Pravastatin therapy initiated at the time of complete coronary revascularization was associated with a reduced risk of cardiac mortality in patients with diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: